bullish
Roche Holding (ROG SW): Despite Patent Cliff Growth Momentum to Continue Backed by New Launches
315 Views20 Apr 2022 15:48
SUMMARY
- Roche Holding AG (ROG SW) is well-positioned for single-digit revenue growth, as strong uptake of new products is offsetting revenue loss from patent expired products due to biosimilar competition.
- New drugs, especially Hemlibra, Ocrevus, and Tecentriq are on a high growth trajectory, which is expected to continue, with no dependency on the COVID-19.
- Recently, Roche received FDA approvals for two new ophthalmology products. Both of them have potential blockbuster sales opportunity. Two more drugs are expected to be launched this year.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
x